H
Howard A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 593
Citations - 40779
Howard A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 80, co-authored 568 publications receiving 34783 citations. Previous affiliations of Howard A. Burris include American Society of Clinical Oncology.
Papers
More filters
Proceedings ArticleDOI
Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.
Jeffrey R. Infante,Amita Patnaik,Suzanne F. Jones,Kiriakos P. Papadopoulos,Johanna C. Bendell,Drew W. Rasco,Kevin M. Bellew,Donna S. Cox,Michael Durante,Joohyun Jennifer Park,Howard A. Burris,Ngocdiep T. Le,Anthony W. Tolcher +12 more
TL;DR: Despite evidence of clinical activity in this heavily pretreated patient population, the toxicity profiles limit the ability to give MEK+EVE and an RP2R was not identified.
Journal ArticleDOI
First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.
David S. Hong,Ignacio Garrido-Laguna,Ian E. Krop,Vivek Subbiah,Theresa L. Werner,Christine M Cotter,Erika Hamilton,Karen Velastegui,Dawei Xuan,Roberto Bugarini,Ashwin Gollerkeri,Howard A. Burris +11 more
TL;DR: Once the maximum tolerated dose (MTD) is determined, expansion cohorts for patients with EFNA4-expressing TNBC and platinum-resistant OVCA are planned.
Journal ArticleDOI
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Joyce F. Liu,Howard A. Burris,Judy S. Wang,Lisa Barroilhet,Martin Gutierrez,Yulei Wang,Anjali Vaze,Renee Commerford,Stephanie Royer-Joo,Voleak Choeurng,Eric W. Humke,Kathleen N. Moore +11 more
TL;DR: DMUC4064A as mentioned in this paper is a humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E.
Journal Article
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
Geoffrey I. Shapiro,Rebecca Kristeleit,Mark R. Middleton,Howard A. Burris,L. R. Molife,Jeff Evans,Richard H. Wilson,Patricia LoRusso,James Spicer,Véronique Diéras,Manish R. Patel,E. Dominy,Dayna Simpson,Heidi Giordano,Andrew R. Allen,Sarah Jaw-Tsai,Ruth Plummer +16 more
Proceedings ArticleDOI
Abstract P1-16-05: MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer
Anthony D. Elias,Howard A. Burris,Patel,Lee S. Schwartzberg,Jennifer K. Richer,E Kavalerchik,S Stopatschinskaja,Jacqueline A. Gibbons,D Markova,Joyce Steinberg,TA Traina +10 more
TL;DR: The safety profile for the combination of daily ENZA with FUL appears to be consistent with the published data for ENZA and FUL monotherapies, indicating no PK drug interaction.